US · OTLK
Outlook Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Iselin, NJ 08852
- Website
- outlooktherapeutics.com
Price · as of 2025-09-30
$0.26
Market cap 17.31M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | $382,411.58 | +145,847,184.52% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $0.00 | $16,358.01 | |||
| 2016 | $401.60 | $170.85 | $0.00 | $0.00 | $19,544.07 |
| 2017 | $201.60 | $908,071.44 | $0.00 | $0.00 | $0.00 |
| 2018 | $102.56 | $98,128,639.42 | $0.00 | $0.00 | $1,962.52 |
| 2019 | $22.20 | $8.88 | $7,848.82 | $0.00 | $0.00 |
| 2020 | $26.40 | $19.78 | |||
| 2021 | $29.00 | ||||
| 2022 | $19.82 | ||||
| 2023 | $8.52 | ||||
| 2024 | $1.52 | ||||
| 2025 | $2.05 | $637,351.26 | $0.00 |
AI valuation
Our deep-learning model estimates Outlook Therapeutics, Inc.'s (OTLK) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.26
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$382,411.58
+145,847,184.52% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| OTLK | Outlook Therapeutics, Inc… | $0.26 | 17.31M | — | +145,847,185% | — | — | 0.00 | 0.00 | 50.46 | 123242.30 | — | 0.00 | 46.49% | -4744.25% | -4416.22% | 387.88% | 0.00% | -671.81% | -0.01 | -236.86 | 0.38 | 0.18 | 123243.42 | -5591.00% | — | 7534010988.00% | -72659652.79% | -1.13 | 259.00% | 0.00% | 0.00% | 10984444.51% | 116837.47 | 0.15 | -5543064.49 | -47.47 |
| COEP | Coeptis Therapeutics, Inc… | $12.04 | 42.29M | — | — | — | — | -1.87 | 6.40 | — | -2.25 | -0.32 | 7.72 | 0.00% | — | — | -290.10% | -247.64% | -128.12% | 0.44 | -25.38 | 0.23 | 0.12 | -0.09 | 58072.00% | — | -815.00% | -32.60% | -1.47 | -163.77% | 0.00% | 0.00% | 0.00% | -2.11 | -3.20 | — | -17.20 |
| CUE | Cue Biopharma, Inc. | $0.28 | 22.08M | +11,310% | +57% | — | — | -1.52 | 3.54 | 6.67 | -1.26 | — | 3.54 | 100.00% | -446.86% | -437.97% | -149.03% | -1327.36% | -86.80% | 0.51 | -52.14 | 1.84 | 1.78 | 0.36 | -3514.00% | 6916.00% | -892.00% | -58.74% | -2.65 | -1164.08% | 0.00% | 0.00% | 0.00% | -1.14 | -1.30 | 5.11 | -15.88 |
| EQ | Equillium, Inc. | $1.82 | 64.65M | +1,406% | -79% | — | — | -3.51 | 1.48 | 0.69 | -0.81 | — | 1.48 | 100.00% | -20.12% | -19.63% | -38.75% | 80.29% | -21.19% | 0.02 | — | 3.93 | 3.73 | 2.34 | -3947.00% | 1389.00% | -1247.00% | -67.56% | -2.99 | 185.55% | 0.00% | 0.00% | 0.00% | -0.74 | -0.32 | 0.15 | -6.59 |
| HOWL | Werewolf Therapeutics, In… | $0.60 | 29.13M | +4,114% | — | — | +21,192% | -0.76 | 0.73 | 28.28 | 0.32 | -1.37 | 0.73 | 3.77% | -3904.19% | -3740.85% | -76.33% | -517.61% | -46.74% | 0.51 | -15.81 | 7.45 | 7.31 | 1.15 | 5524.00% | -9055.00% | 6908.00% | -105.90% | -3.70 | -396.98% | 0.00% | 0.00% | 0.00% | 0.28 | 0.37 | -10.93 | -4.95 |
| IOBT | IO Biotech, Inc. | $0.35 | 25.11M | — | — | — | — | -0.62 | 1.26 | — | -0.01 | — | 1.26 | 0.00% | — | — | -106.00% | 1021.32% | -87.44% | 0.04 | — | 3.33 | 3.14 | 0.62 | -2677.00% | — | 1434.00% | -138.96% | -4.23 | 884.12% | 0.00% | 0.00% | 0.00% | -0.01 | -0.01 | — | -9.54 |
| IPSC | Century Therapeutics, Inc… | $2.32 | 202.78M | +1,581% | -88% | — | — | -0.41 | 0.32 | 7.82 | 0.75 | — | 0.41 | 100.00% | -2096.48% | -1920.87% | -73.14% | -320.94% | -35.46% | 0.33 | — | 1.50 | 1.47 | 0.04 | -3000.00% | 19481.00% | 804.00% | -214.09% | -0.85 | -256.24% | 0.00% | 0.00% | 10.59% | 0.61 | 0.76 | -12.74 | -3.99 |
| MDCX | Medicus Pharma Ltd. Commo… | $1.53 | 37.8M | — | — | — | — | -2.63 | 9.36 | — | -2.29 | — | 9.36 | 0.00% | — | — | -525.44% | 1700.21% | -295.90% | 0.10 | -35.21 | 2.33 | 1.81 | 0.34 | -2810.00% | — | 14643.00% | -34.93% | -4.44 | 1558.23% | 0.00% | 0.00% | 7.24% | -2.28 | -2.49 | — | -6.04 |
| NRXP | NRx Pharmaceuticals, Inc. | $1.86 | 32.15M | — | — | — | — | -0.91 | -0.98 | — | -1.16 | — | -0.98 | 0.00% | — | — | 143.76% | 156.03% | -458.25% | -0.28 | -18.26 | 0.15 | 0.07 | -0.21 | -3995.00% | — | -5089.00% | -46.61% | -0.49 | 84.23% | 0.00% | 0.00% | 0.00% | -1.42 | -2.63 | — | -130.11 |
| SPRB | Spruce Biosciences, Inc. | $54.94 | 31.88M | +1,366% | +1,346% | — | +7,284% | -20.08 | 36.96 | 216.90 | -19.54 | -498.08 | 36.96 | 100.00% | -1143.37% | -1079.94% | -100.70% | 501.62% | -71.12% | 0.10 | -182.90 | 2.90 | 2.54 | 0.68 | 403.00% | -5132.00% | 6815.00% | -5.25% | -3.67 | 499.95% | 0.00% | 0.00% | 0.00% | -18.33 | -18.39 | 209.57 | 28.03 |
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
- CEO
- Robert Charles Jahr
- Employees
- 23
- Beta
- -0.07
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($382,411.58 ÷ $0.26) − 1 = +145,847,184.52% (DCF, example).